The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas

SIMPLE SUMMARY: The sensitivity to PARP inhibitors (PARPi) is related to tumor-specific defects in homologous recombination (HR) and extends beyond BRCA1/2-related deficiencies. A robust method to identify HR-deficient (HRD) carcinomas is therefore of utmost clinical importance. In this study, we ev...

Descripción completa

Detalles Bibliográficos
Autores principales: van Wijk, Lise M., Vermeulen, Sylvia, Meijers, Matty, van Diest, Manuela F., ter Haar, Natalja T., de Jonge, Marthe M., Solleveld-Westerink, Nienke, van Wezel, Tom, van Gent, Dik C., Kroep, Judith R., Bosse, Tjalling, Gaarenstroom, Katja N., Vrieling, Harry, Vreeswijk, Maaike P. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650677/
https://www.ncbi.nlm.nih.gov/pubmed/33003546
http://dx.doi.org/10.3390/cancers12102805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650677/
https://www.ncbi.nlm.nih.gov/pubmed/33003546
http://dx.doi.org/10.3390/cancers12102805

Ejemplares similares